Genmab — August 2017
-
Jeg ser også nyheden som ret vigtig - Jan sagde også på sidste CC, at de pt taler med FDA/EMA om de videre skridt - her må SG også være tiltredse med mulighederne fremadrettet. og som i skriver oral præsentation på ESMO - og en Judith Klimovsky der også fremhævede at data var rigtig gode når man ser dem i sin helhed
-
-
Thomas, hørte en analytiker på Børsen play udtale at han forventede et topsalg på 1,5 mia USD. Så multi.....? Men h
eraf vil Genmab jo få 50 % -
Johnson & Johnson's Darzalex Is An Emerging Threat To The Primacy Of Celgene's Revlimid - https://seekingalpha.com/article/4102607-johnson-and-johnsons-darzalex-emerging-threat-primacy-celgenes-revlimid
-
- linje godkendelsen i Canada (10% af US-marked) kan også være tæt på"The CADTH pCODR review of Darzalex is positive and the pERC (pCODR Expert Review Committee) recommendation is that Darzalex should receive reimbursement in Canada for second-line multiple myeloma and beyond. In second-line myeloma the pERC notes that Darzalex must be used either in combination with Revlimid (POLLUX trial) or Velcade (CASTOR) trial and that patients should just have received one prior line of therapy". (Novod)
-
Danske Banks seneste analyse: Tisotumab. 25% sandsynlighed for lancering i 2022. NPV per aktie 60 DKK.
-
1449
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind